SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 11.11 |
| Enterprise Value ($M) | 8.64 |
| Book Value ($M) | 0.69 |
| Book Value / Share | 0.42 |
| Price / Book | 15.98 |
| NCAV ($M) | 0.68 |
| NCAV / Share | 0.41 |
| Price / NCAV | 16.45 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -93.05 |
| Return on Assets (ROA) | -8.65 |
| Return on Equity (ROE) | -20.21 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.08 |
| Current Ratio | 3.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.69 |
| Assets | 2.71 |
| Liabilities | 2.01 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Bailey Gregory | 30.70 | 378.44 | |
| 13D/A | Mellon James | 16.70 | ||
| 13G/A | Armistice Capital, Llc | 4.99 | -97.23 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 208,987 | 585,312 | 35.71 | |
| 16,629 | 63,950 | 26.00 | |
| 36,436 | 184,522 | 19.75 | |
| 215,895 | 707,479 | 30.52 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PROK – ProKidney Corp. | PRPH – ProPhase Labs, Inc. |
| PRQR – ProQR Therapeutics N.V. | PTIX – Protagenic Therapeutics, Inc. |
| PTPI – Petros Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io